← Back to Clinical Trials
Recruiting Phase 2 NCT05732883

NCT05732883 The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05732883
Status Recruiting
Phase Phase 2
Sponsor Tseung Kwan O Hospital, Hong Kong
Condition Voice Change
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-07-01
Primary Completion 2026-06-30

Trial Parameters

Condition Voice Change
Sponsor Tseung Kwan O Hospital, Hong Kong
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-07-01
Completion 2026-06-30
Interventions
DexamethasoneNormal saline

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Thyroidectomy is a standard procedure for benign and malignant pathologies of the thyroid gland. Each year, some 100 total thyroidectomies are performed in Kowloon East Cluster, Hospital Authority, Hong Kong. Total thyroidectomy is associated with voice dysfunction and temporary hypocalcaemia in up to 80% and 50%, respectively. Previous study from our institute showed a 3% rate of permanent vocal cord palsy and 16% of permanent hypoparathyroidism requiring calcium and/or vitamin D supplements. The use of dexamethasone has been studied in the past in total thyroidectomy patients and has been shown to be safe and effective in improving post-operative nausea and vomiting. No complications or drug related side effects were associated with a single dose of steroid. Recent studies have also shown that Dexamethasone is effective in improving voice outcome and hypocalcaemia in thyroidectomy patients. The investigators aim to study the effect of Dexamethasone in post-operative voice outcome and hypocalcaemia. Objective assessment of the vocal cords during phonation will be performed pre-operative and post-operatively. Serum Calcium level will be monitored.

Eligibility Criteria

Inclusion Criteria: * Aged 18 or above * Patients undergoing total thyroidectomy for benign pathologies * MNG * Toxic nodular goitre * Graves' disease Exclusion Criteria: * Non-communicable patients * Patients contraindicated for steroid (DM, Hepatitis carrier, Tuberculosis, peptic ulcer disease) * Patients contraindicated for analgesics including Panadol, Celebrex, Tramadol or Levobupivacaine * Malignant thyroid disease * Patients with previous thyroid surgery, or neck surgery * Pre-existing hoarseness of voice of any cause or pre-existing vocal cord palsy * Pregnancy / Lactating female patients * Pre-existing renal disease / autoimmune disease on steroids * Patients who require steroid cover during operation e.g. hydrocortisone perioperatively

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology